Mesoblast Limited (MSB)

Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today Ľ it's FREE! Already a member? Login now!

General Information
Company Name: Mesoblast Limited
Stock Code: MSB
GICS Sub-Industry: Biotechnology
Market Cap ($M): 1,178
Equiv. Shares (M): 324

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
 $ 3.630 $ 3.720 $ 3.720 $ 3.630 $ 3.620 429,730 $ 0.010  0.276 %

Current Broker Consensus Recommendation more
Recommendation: Buy (2)
Recommendation Date: 26th Mar 2015
Brokers Surveyed: 2

Company Overview

Business Description:
Mesoblast Limited (MSB) is an Australian company engaging in the development of biologic products for the broad field of regenerative medicine. The key focus is on research and development of adult Mesenchymal Precursor Cells (MPCs), Mesenchymal Stem Cells (MSCs), Dental Pulp cells and Adipose cells. Its intellectual property covers a range of applications in key markets including the United States, Europe, Japan and China.

Strategy Analysis:
MSB is developing a proprietary stem cell technology for the treatment of orthopaedic conditions such as bone fractures, degenerated knee cartilage and vertebral disc degeneration. Through an investment in and subsequent merger with Angioblast Systems, Inc. MSB is also developing stem cell treatments for cardiac and vascular diseases, and other degenerative conditions. MSB's strategy is to maximise shareholder value through both corporate partnerships and the rapid and successful completion of pre-clinical and clinical milestones to commercialise the technology. The firm already has TGA approval to manufacture and distribute patient-specific adult stem cell products to hospitals and physicians across Australia; this is the first culture-expanded adult stem cell product to receive manufacturing approval anywhere in the world. Mesoblast reported a net loss of $27.79m for the half-year ended 31 December 2012 (31 Dec 2011: $17.6m). The increased loss was driven by a reduction in revenue from continuing operations and other income of $4.3m and an increase in expenses from continuing operations of $5.9m. Revenues from ordinary activities were $14.73m, down 22% from the same period last year. Diluted EPS was (9.69) cents compared to (15.52) cents last year. The net operating cash outflow was $30.52m compared to an outflow of $36.89m in the pcp. No dividend was declared. In the second half of the financial year, the Company expects to continue to report on clinical outcomes from a number of Phase 2 programs and to initiate new programs in line with the overall corporate strategy.

Financial Summary
Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2016  F -122.7 -37.7 -5.5 -9.6 0.0 0.0 0.0
2015  F -131.5 -39.8 17.3 -9.1 0.0 0.0 0.0
2014  A -108.5 -34.0 14.7 -16.3 0.0 0.0 0.0
Source: Morningstar analyst estimates.

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2014 A 2015 F 2016 F 2014 A 2015 F 2016 F 2014 A 2015 F 2016 F
Bionomics (BNO) $196 M -- -- -- 61.0390 -- 4.7667 0.00 0.00 0.00
CSL (CSL) $43,058 M 0.0899 0.3357 0.0809 32.0650 24.0067 22.2104 1.31 1.74 1.98
Mesoblast (MSB) $1,174 M -- -- -- -- -- -- 0.00 0.00 0.00
Starpharma (SPL) $140 M -- -- -- -- -- -- 0.00 0.00 0.00
Sirtex Medical (SRX) $1,155 M 0.2906 0.6080 0.2575 49.4673 30.7634 24.4641 0.69 0.94 1.42

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
MSB -- -- 2.01 10.00 70.6
Market 0.88 16.6 1.30 2.38 1.59
Sector 0.81 16.7 2.72 1.27 7.80

Name Position Start Date
Professor Silviu Itescu Chief Executive Officer,Executive Director 08 June 2004
Mr Brian Jamieson Non-Executive Chairman 22 November 2007
Mr Michael Robert Spooner Non-Executive Director 29 September 2004
Mr Donal O'Dwyer Non-Executive Director 29 September 2004
Dr Ben-Zion Weiner Non-Executive Director 09 May 2012
Dr Eric A Rose Non-Executive Director 15 April 2013
Mr William M Burns Non-Executive Director 06 March 2014

Name Position
Charlie Harrison Company Secretary

Substantial Shareholders
Holding Name
68,244,642 (21.56%) Silviu Itescu
21,770,000 (6.80%) Capital Research Global Investors
18,029,407 (5.56%) Thorney Holdings Pty Ltd and Thorney Pty Ltd and associated entities
36,782,943 (11.40%) M&G Investment Funds
55,785,806 (17.62%) Cephalon International Holdings Inc

Calendar of Events
Date Event
11 February 2016 Report (Interim)
22 October 2015 Report (Annual)
25 August 2015 Report (Prelim)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at


Trade Shares Online from $19.95^
Free Guides

The SMH Guide to Estate Planning

Everyone wants their financial affairs to be in the best possible state when they die so that their loved ones can enjoy the benefits of their legacy without dispute or conflict.

More details...


Markets melt up

By Michael McCarthy (chief market strategist, CMC Markets) 19/12/2014 | Traders and investors caught short heading into the FOMC scrambled for cover in Europe and the US, in many cases driving indices to their best one day performance for 2015.

Aussie Investors take their foot off the accelerator

By Betty Lam (Sales Trader, CMC Markets) 18/12/2014 | Lead by the Fed-fervour offshore, Australians shares jumped on the Yellen cheer wagon. The material and energy stocks were back in vogue as both sectors gained over 3% in morning trade.

Fed Feeds Frenzy

By Michael McCarthy (chief market strategist, CMC Markets) 18/12/2014 | In spite of a frenzied pre-mortem, a benign statement from the US Federal Reserve‚Äôs Open Market Committee and steadying commodity markets drove investors back into share markets overnight. A calmer, stronger ruble helped offset European growth fears, highlighted in the overnight session by further declines in inflation.

Household brands Woolworths and Telstra Heavy Lifting

By Betty Lam (Sales Trader, CMC Markets) 11/12/2014 | Offshore jitters sent ripples through to Australian stocks. The open saw the local equities take 65 points off the index, catalysed by a mass-exit in energy stocks, yet again.

Steady open as Woodside investors wait on details of possible Wheatstone acquisition

By Ric Spooner (Chief Market Analyst, CMC Markets) 10/12/2014 | Yesterday‚Äôs news on Greek politics and China‚Äôs bond market came at a time when US and European stock markets have extended rallies and pushed valuations higher. This makes those markets vulnerable to downward corrections as profit takers act to avoid missing out.

MYEFO and Lima - December could be nasty.

BR Securities Australia Pty Ltd 2/12/2014 | December 2014 could go down as a nasty moment in Australian finance. MYEFO will reveal a deteriorating budget deficit and the UNFCCC meeting in Lima, Peru will provide the agreement, to be ratified in Paris in 2015, on how much (or little) CO2 is to be allowed into the atmosphere from 2020.


Sponsored Links